Table 2.

SIRs of selected cancers among WTCHP responders, 2001–2008: residents of New York, Connecticut, Pennsylvania, and New Jersey (n = 20,984).

Cancer	Unrestricteda				Restrictedb
	Observed	Expected	SIR	95% CI	Observed	Expected	SIR	95% CI
All sites	575	498.8	1.15	1.06–1.25	302	286.1	1.06	0.94–1.18
Oral cavity and pharynx	21	17.3	1.21	0.75–1.86	10	10.0	1.00	0.48–1.84
Digestive system	86	90.8	0.95	0.76–1.17	51	52.8	0.97	0.72–1.27
Esophagus	11	6.6	1.67	0.83–2.98	7	3.9	1.77	0.71–3.65
Stomach	11	9.1	1.20	0.60–2.16	7	5.3	1.33	0.53–2.74
Colon and rectum	44	44.4	0.99	0.72–1.33	25	25.7	0.97	0.63–1.43
Liver and intrahepatic bile duct	7	11.9	0.59	0.24–1.22	6	6.9	0.86	0.32–1.88
Lung and bronchus	43	48.4	0.89	0.64–1.20	18	29.1	0.62	0.37–0.98
Soft tissue including heart	11	4.9	2.26	1.13–4.05
Melanoma of the skin	20	21.6	0.93	0.57–1.43	12	11.9	1.01	0.52–1.77
Breast	26	28.8	0.90	0.59–1.32	11	14.9	0.74	0.37–1.32
Prostate	129	106.8	1.21	1.01–1.44	82	66.5	1.23	0.98–1.53
Testis	16	12.2	1.31	0.75–2.13	7	5.5	1.27	0.51–2.62
Urinary bladder	29	21.2	1.37	0.92–1.96	15	12.7	1.18	0.66–1.94
Kidney and renal pelvis	31	22.2	1.39	0.95–1.98	17	12.7	1.34	0.78–2.14
Brain and other nervous system	12	9.8	1.22	0.63–2.13	7	5.2	1.34	0.54–2.77
Thyroid	39	16.3	2.39	1.70–3.27	26	8.3	3.12	2.04–4.57
Hematological	74	54.5	1.36	1.07–1.71	23	29.8	0.77	0.49–1.16
Hodgkin lymphoma	8	6.6	1.21	0.52–2.38
Non-Hodgkin lymphoma	38	28.0	1.36	0.96–1.87	13	15.3	0.85	0.45–1.45
Myeloma	9	6.4	1.41	0.64–2.67
Leukemia	19	13.5	1.41	0.85–2.19
aThe interval between 9/11/01 and the earlier of 31 December 2008 and time of death.bPerson-time and cases starting 6 months after registration in WTCHP.